NCT06266143View on ClinicalTrials.gov

A Trial of Y101D in Combination With Gemcitabine and Albumin Paclitaxel in Patients With Advanced Pancreatic Cancer

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

February 8, 2023

Primary Completion Date

March 21, 2025

Study Completion Date

October 20, 2025

Conditions
Advanced Pancreatic Adenocarcinoma
Interventions
DRUG

Y101D

Intravenous infusion of Y101D at day1, combined with Gemcitabine and Nab-Paclitaxel IV infusion at day1, 8, a 21-day cycle. After 6 cycles, Y101D and Gemcitabine infusion is applied as the maintenance treatment.

Trial Locations (1)

430022

Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan

All Listed Sponsors
lead

Wuhan YZY Biopharma Co., Ltd.

INDUSTRY